Displaying drugs 2751 - 2775 of 3721 in total
Fluorescein lisicol
Fluorescein lisicol has been used in trials studying the diagnostic of Pharmacokinetics, Hepatic Cirrhosis, Hepatitis, Viral, Human, Nonalcoholic Steatohepatitis, and Non-Alcoholic Fatty Liver Disease.
Investigational
Sulisobenzone
Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations . It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage .
The UV-filter substance, sulisobenzone (BP-4) is widely...
Experimental
B7-H3-specific chimeric antigen receptor T cells
Investigational
Anti-CD7 CAR T-cell therapy
Investigational
EHP-102
Investigational
Mavorixafor
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Investigational
alpha-Naphthoflavone
Experimental
Berubicin
Investigational
Exbivirumab
Exbivirumab is an investigational monoclonal antibody. It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.
Investigational
Olokizumab
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome....
Investigational
Patidistrogene bexoparvovec
Investigational
Odanacatib
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
BNT162b1 SARS-CoV-2 Vaccine
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin...
Investigational
Matched Description: … a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% …
TAK-603
Investigational
(6R)-Folinic acid
Experimental
6S-5,6,7,8-Tetrahydrobiopterin
Experimental
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Cinitapride
Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
Investigational
Zolazepam
Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine. Zolazepam is typically used in combination with the NMDA antagonist tiletamine or the α2 adrenoceptor agonist xylazine. It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that...
Vet approved
Matched Iupac: … 4-(2-fluorophenyl)-1,3,8-trimethyl-1H,6H,7H,8H-pyrazolo[3,4-e][1,4]diazepin-7-one …
Matched Mixtures name: … Zoletil 50 Injectable Anaesthetic …
Matched Mixtures name: … Zoletil 50 Injectable Anaesthetic …
8-oxo-dGMP
Experimental
Displaying drugs 2751 - 2775 of 3721 in total